{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.3"},{"groupId":"OG001","value":"23.6"},{"groupId":"OG002","value":"20.0"},{"groupId":"OG003","value":"24.3"},{"groupId":"OG004","value":"22.0"},{"groupId":"OG005","value":"23.1"},{"groupId":"OG006","value":"39.7"},{"groupId":"OG007","value":"59.7"},{"groupId":"OG008","value":"34.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"89"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"37"},{"groupId":"OG004","value":"50"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"78"},{"groupId":"OG007","value":"62"},{"groupId":"OG008","value":"23"}],"units":"Participants"}],"description":"Criteria for PCI changes in ECG (12-lead) were defined as: no sinus rhythm; PR interval \\>=220 msec and increase of \\>=20 msec; QRS interval \\>=120 msec; QT interval corrected using the Fridericia formula (QTcF) and QT interval corrected using the Bazett formula (QTcB) \\>500 msec or increase of \\>60 msec; heart rate \\<=45 beats per minute (bpm) or \\>=120 bpm or decrease/increase of \\>=15 bpm.","groups":[{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP2L IM-R CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"OG000","title":"Bosutinib 500 mg, CP2L-CML IM-R (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP2L IM-I CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"OG001","title":"Bosutinib 500 mg, CP2L-CML IM-I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I, D and NI R/I or IM R/I and NI-I CML.","id":"OG002","title":"Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and D-R CML.","id":"OG003","title":"Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and D-I CML.","id":"OG004","title":"Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and NI-R CML.","id":"OG005","title":"Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2)"},{"description":"All participants who received bosutinib 500 mg orally once daily in AP CML who were IM R/I or multiple tyrosine kinase inhibitor (Multi-TKI): IM, D and/or NI R/I.","id":"OG006","title":"AP-CML Total (Part 2)"},{"description":"All participants who received bosutinib 500 mg orally once daily in blast phase (BP) CML who were IM R/I or Multi-TKI: IM, D and/or NI R/I.","id":"OG007","title":"BP-CML Total (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with Ph+ ALL","id":"OG008","title":"Bosutinib 500 mg, Ph+ ALL (Part 2)"}],"paramType":"NUMBER","populationDescription":"Safety population included all participants who receive at least one dose of study medication. 'N' (Number of Participants Analyzed) signifies number of participants who were evaluable for this measure.","reportingStatus":"POSTED","timeFrame":"Baseline, 0 (pre-dose), 2, 4, 6 hours on Day 1, 0 (pre-dose), 2, 4, 6, 20-23 hours on Day 21, and end of treatment visit","title":"Percentage of Participants With On-treatment PCI Change From Baseline in Electrocardiogram (ECG) Findings","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}